Dr. Reddy's, XenoPort strike deal for psoriasis therapy

XenoPort Inc. (NASDAQ:XNPT) granted Dr. Reddy%27s Laboratories Ltd. (NYSE:RDY) exclusive, U.S. rights to develop and commercialize XP23829, which has completed a Phase II

Read the full 231 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE